Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) announced that interim data from its Phase 1b/2 EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) will be presented as a late-breaking oral session at the 2021 TCT Meetings, scheduled for February 12, 2021. The study, led by John Koreth, aims to demonstrate the safety and efficacy of itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM pathway, important in T cell activity related to autoimmune disorders. Equillium is focused on treating severe autoimmune and inflammatory conditions with high unmet medical needs.

Positive

• Acceptance of interim data for presentation at a significant industry conference.
• Itolizumab is positioned to address a critical medical need in treating aGVHD.

Negative

• None.

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Title: Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate Study
First Author: John Koreth, MBBS, Ph.D. director of translational research, stem cell transplantation, Dana-Farber Cancer Institute
Date and Time: Friday, February 12 at 2:00 p.m. CST / 3:00 p.m. EST
Abstract ID Number: LBA4

About Itolizumab
Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
ir@equilliumbio.com

Media Contact
Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
katherine.smith@canalecomm.com

FAQ

What is the latest update from Equillium regarding itolizumab?

Equillium announced that the interim data from its Phase 1b/2 EQUATE study of itolizumab will be shared at the 2021 TCT Meetings on February 12, 2021.

When will the interim results of the EQUATE study be presented?

The interim results of the EQUATE study will be presented on February 12, 2021, at 2:00 p.m. CST / 3:00 p.m. EST.

What is the significance of itolizumab in treating aGVHD?

Itolizumab is designed to target the CD6-ALCAM pathway, potentially offering a novel treatment option for acute graft-versus-host disease.

Who is leading the research on itolizumab for aGVHD?

John Koreth, MBBS, Ph.D., is leading the research as the director of translational research at Dana-Farber Cancer Institute.